October 17, 2026
Kurt Mussina discusses why site ownership alone does not create an integrated operating model — and what sponsors and CROs should look for beyond site count.
Published by Applied Clinical Trials
During the 2026 SCRS Global Site Solutions Summit, Paradigm Clinical Research CEO Kurt Mussina spoke with Applied Clinical Trials about an important distinction in the ongoing consolidation of the clinical research site sector: owning a group of sites is not the same as operating those sites as one integrated business.
In the interview, Mussina describes Paradigm’s nine locations as one business operating across multiple markets, with common SOPs, a single management structure and shared operational infrastructure. He also discusses why sponsors and CROs evaluating multisite organizations should look beyond an investigator’s individual experience to understand the strength, stability and performance of the broader team and systems supporting that investigator.
The interview covers:
- What distinguishes site ownership from true operational integration
- Why common systems, SOPs and management structure matter across a multisite organization
- The importance of the clinical and operational team surrounding the investigator
- How organizational structure can affect consistency and execution across locations
Watch the full interview from Applied Clinical Trials:
The Difference Between Owning a Group of Sites and Operating Them as One Integrated Platform
About Paradigm Clinical Research
Paradigm Clinical Research is a clinical research site organization supporting phase I–IV programs across metabolic disease, dermatology, pulmonology, neurology, psychiatry, ophthalmology, and vaccines and infectious disease. Paradigm operates wholly owned clinical trial sites with centralized governance and infrastructure designed to minimize operational variability across sites, a common challenge in multi-site clinical trials.
In collaboration with more than 40 board-certified principal investigators, the company delivers expertly conducted clinical studies and access to diverse and specialty patient populations for sponsors and CRO partners. Additional information is available at www.paradigm-research.com.